Normal view

Received — 10 September 2026 ⏭ Molecular Therapy

Molecular Therapy
Targeting EZH2 and EGFR Therapeutic Vulnerabilities of TNBC with a Single Chemical Entity Confers Preclinical Treatment Advantage Saumya Ranjan Satrusal · Arpita Banerjee · Arpon Biswas · Gaurava Srivastava · Indranil Chatterjee · Muqtada Ali Khan · Biswajit Mandal · Kiran Tripathi · Abhipsa Sinha · Ayushi Verma · Priyanka Rai · Mahmood Akbar · Shivansh Kumar · Sohini Chatterjee · Kulranjan Singh · Aamir Nazir · Rabi Sankar Bhatta · Gautam Panda · Dipak Datta
Utilizing medicinal chemistry approach, Datta and colleagues demonstrate that EZH2-EGFR dual targeting halts protein translation in TNBC and inhibits tumor growth and metastasis in preclinical animal models.
25 August 2026 at 08:00

Targeting EZH2 and EGFR Therapeutic Vulnerabilities of TNBC with a Single Chemical Entity Confers Preclinical Treatment Advantage

By: Saumya Ranjan Satrusal · Arpita Banerjee · Arpon Biswas · Gaurava Srivastava · Indranil Chatterjee · Muqtada Ali Khan · Biswajit Mandal · Kiran Tripathi · Abhipsa Sinha · Ayushi Verma · Priyanka Rai · Mahmood Akbar · Shivansh Kumar · Sohini Chatterjee · Kulranjan Singh · Aamir Nazir · Rabi Sankar Bhatta · Gautam Panda · Dipak Datta

25 August 2026 at 08:00

Utilizing medicinal chemistry approach, Datta and colleagues demonstrate that EZH2-EGFR dual targeting halts protein translation in TNBC and inhibits tumor growth and metastasis in preclinical animal models.